This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Recombinant human thrombin, rh Thrombin, rThrombin, thrombin alfa
Description: rhThrombin is a recombinant form of human thrombin for hemostasis (ie to stop unwanted bleeding). Thrombin is a protease (an enzyme that cleaves proteins) which plays a critical role in hemostasis (the stopping of bleeding). It converts fibrinogen into an active form and also activates factors XI, V, and VIII of the coagulation cascade. Thrombin also acts on receptors to activate platelets and produce pro-inflammatory and pro-fibrotic effects.
ZymoGenetics and Bayer
In June 2007, ZymoGenetics announced it entered into multi-year, domestic and global license and collaboration agreements with Bayer HealthCare to maximize the potential of ZymoGenetics' recombinant human thrombin (rThrombin). ZymoGenetics retains U.S. product rights.
In 2007, ZymoGenetics expects to receive $70 million from Bayer HealthCare, including a $30 million upfront payment and a $40 million milestone payment due upon approval of rThrombin in the U.S. ZymoGenetics is eligible to receive up to $128 million in additional development and sales-based milestones over the course of the agreement.
In the United States, Bayer HealthCare will co-promote rThrombin with ZymoGenetics for a three-year period beginning at launch. ZymoGenetics will compensate Bayer HealthCare for its efforts in the U.S. by paying a tiered commission of up to 20% on U.S. sales and up to $20 million in sales bonus payments upon achievement of certain U.S....See full deal structure in Biomedtracker
Partners: Bayer AG Bristol-Myers Squibb Company
Additional information available to subscribers only: